Naoxintong Retards Atherosclerosis by Inhibiting Foam Cell Formation through Activating PPARα Pathway

BACKGROUNDS: We recently reported that Naoxintong (NXT), a China Food and Drug Administration (FDA)-approved cardiac medicine, could reduce the plaque size, but the underlying mechanism remains elusive now. OBJECTIVE: In this study, we investigated the effects of NXT on foam cell accumulation both i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zeng, Shi, Huairui, Zhao, Huan, Dong, Zhen, Zhao, Buchang, Weng, Xinyu, Liu, Rongle, Hu, Kai, Zou, Yunzeng, Sun, Aijun, Ge, Junbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463403/
https://www.ncbi.nlm.nih.gov/pubmed/30734676
http://dx.doi.org/10.2174/1566524019666190207143207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463403/
https://www.ncbi.nlm.nih.gov/pubmed/30734676
http://dx.doi.org/10.2174/1566524019666190207143207

Ejemplares similares